AU1615895A
(en)
*
|
1994-03-31 |
1995-10-12 |
Bristol-Myers Squibb Company |
Imidazole-containing inhibitors of farnesyl protein transferase
|
US5523456A
(en)
*
|
1994-09-29 |
1996-06-04 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5652257A
(en)
*
|
1994-09-29 |
1997-07-29 |
Merck & Co., Inc. |
Heterocycle-containing inhibitors of farnesyl-protein transferase
|
JPH10508005A
(ja)
*
|
1994-09-29 |
1998-08-04 |
メルク エンド カンパニー インコーポレーテッド |
チオールを有しないファルネシル−タンパク質トランスフェラーゼ阻害剤
|
US5972984A
(en)
*
|
1995-06-06 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5756528A
(en)
*
|
1995-06-06 |
1998-05-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
FR2736641B1
(fr)
*
|
1995-07-10 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US5968965A
(en)
*
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5981562A
(en)
*
|
1996-01-30 |
1999-11-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6011029A
(en)
*
|
1996-02-26 |
2000-01-04 |
Bristol-Myers Squibb Company |
Inhibitors of farnesyl protein transferase
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
CA2253934A1
(en)
*
|
1996-05-22 |
1997-11-27 |
Warner-Lambert Company |
Inhibitors of protein farnesyl transferase
|
CO4920227A1
(es)
*
|
1996-12-17 |
2000-05-29 |
Warner Lambert Co |
Histidina-n-bencil glicinamida sustituida con cicloalquilos .
|
FR2757855B1
(fr)
*
|
1996-12-30 |
1999-01-29 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US6013662A
(en)
*
|
1996-12-30 |
2000-01-11 |
Rhone-Poulenc Rorer S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US6124465A
(en)
*
|
1997-11-25 |
2000-09-26 |
Rhone-Poulenc S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US6423689B1
(en)
|
1997-12-22 |
2002-07-23 |
Warner-Lambert Company |
Peptidyl calcium channel blockers
|
AU1600599A
(en)
|
1998-02-27 |
1999-09-15 |
Warner-Lambert Company |
Heterocyclic substituted aniline calcium channel blockers
|
US6166052A
(en)
|
1998-03-11 |
2000-12-26 |
Warner-Lambert Company |
Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
|
WO1999051216A2
(en)
|
1998-04-02 |
1999-10-14 |
R.J. Reynolds Tobacco Company |
3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
|
JP2002513031A
(ja)
|
1998-04-27 |
2002-05-08 |
ワーナー−ランバート・カンパニー |
ファルネシルトランスフェラーゼ阻害剤としての機能化されたアルキルおよびアルケニル側鎖を有するグリシンアミド誘導体
|
AU772575B2
(en)
|
1998-12-10 |
2004-04-29 |
F. Hoffmann-La Roche Ag |
Procollagen C-proteinase inhibitors
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
FR2796641B1
(fr)
|
1999-07-22 |
2001-09-21 |
Aventis Pharma Sa |
Nouveau procede de preparation de composes benzoperhydroisoindole
|
WO2005044780A1
(ja)
*
|
2003-11-10 |
2005-05-19 |
Kyorin Pharmaceutical Co., Ltd. |
アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
HUE035654T2
(en)
|
2006-04-19 |
2018-05-28 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
WO2008106692A1
(en)
|
2007-03-01 |
2008-09-04 |
Novartis Vaccines And Diagnostics, Inc. |
Pim kinase inhibitors and methods of their use
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
JP5452237B2
(ja)
|
2008-02-07 |
2014-03-26 |
杏林製薬株式会社 |
アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
MY174452A
(en)
|
2009-10-14 |
2020-04-19 |
Schering Corp |
Substituted piperidines that increase p53 activity and the uses thereof
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
KR20130006664A
(ko)
|
2010-03-16 |
2013-01-17 |
다나-파버 캔서 인스티튜트 인크. |
인다졸 화합물 및 그의 용도
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
IN2013MN02170A
(no)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
ES2820714T3
(es)
|
2011-10-26 |
2021-04-22 |
Allergan Inc |
Derivados de amida de aminoácidos N-urea sustituidos como moduladores del receptor análogo al receptor 1 de péptido formilado (FPRL-1)
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
JP6854762B2
(ja)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の阻害剤
|
CA2978518C
(en)
|
2015-03-27 |
2023-11-21 |
Nathanael S. Gray |
Inhibitors of cyclin-dependent kinases
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
|
US11142507B2
(en)
|
2015-09-09 |
2021-10-12 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
IL315837A
(en)
|
2017-04-13 |
2024-11-01 |
Sairopa B V |
Anti-SIRP-alpha antibodies
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
US12187701B2
(en)
|
2018-06-25 |
2025-01-07 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
US12173026B2
(en)
|
2018-08-07 |
2024-12-24 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|